Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

This study is testing a three-drug combination — pirtobrutinib, venetoclax, and obinutuzumab — for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CLL or SLL - You have already received treatment for CLL/SLL and need further therapy - You can swallow oral medications - Your kidneys, liver, and bone marrow are functioning adequately - You are in reasonably good physical health (able to care for yourself) **You may NOT be eligible if...** - Your cancer progressed while you were taking venetoclax - You have a history of Richter's syndrome (a transformation of CLL into a more aggressive lymphoma) - You have not had sufficient time (washout period) since your last cancer treatment - You are pregnant or planning to become pregnant without using effective contraception Talk to your doctor to see if this trial is right for you.